Skip to main content
Mohamad Mohty on Muck Rack

Mohamad Mohty

Verified
As seen in: Blood Cancer Journal, Nature, Wiley, Wiley Online Library, The Lancet, Journal of Clinical Oncology, Blood, OncLive, EMJ- European Medical Journal, Targeted Oncology, touchONCOLOGY and
Professor of Hematology; past-president of the EBMT; Chairman of the IACH; Editor in Chief: Bone Marrow Transplant; Clin Hematol Int.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mohamad

Contact Mohamad, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood a

|
By Enrico Maffini, Maud Ngoya, Mohamed Nabil Houhou, Malek Benakli, Mahmoud Aljurf, Khalid Halahleh, Regis de Latour, Igor-Wolfgang Blau, Andrew Clark, Catherine Flynn, Péter Reményi, Ibrahim Yakoub-Agha, Henrik Sengeloev, Cristina Castilla-Llorente, Emma Nicholson, Urpu Salmenniemi, Radovan Vrhovac, Jakob Passweg, Matthias Eder, Etienne Daguindau, Alexandros Spyridonidis, Arnon Nagler, Fabio Ciceri, Mohamad Mohty Verified, Babak Bahar, Maria Losa Maroto
| Nature Verified
Abstract The optimal myeloablative conditioning regimen for adolescents and young adults with acute myeloid leukaemia (AML) is currently unknown. In this retrospective analysis conducted on AML patients aged 18-40 years, in complete remission (CR), who received an allogeneic hematopoietic cell transplantation (HCT) we compared outcomes of different conditioning regimens.
Open in Who Shared Issue with article?

Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities

|
By Arnon Nagler, Jordi Esteve, Jacques-Emmanuel Galimard, Depei Wu, Erlie Jiang, Nathalie Dhedin, Anne Sirvent, Jan Vydra, Jakob Passweg, Bruno Lioure, Jaime Sanz, Jurjen Versluis, Yajing Xu, Cristina Castilla-Llorente, Rodrigo Martino Bufarull, Victoria Potter, Eolia Brissot, Ali Bazarbachi, Bipin N. Savani, Sebastian Giebel, Mohamad Mohty Verified, Fabio Ciceri, Nour Ben Abdeljelil
| Nature Verified
Abstract We compared the presence of additional chromosomal abnormalities (ACAs, n = 345) with a referent group with no ACAs (n = 169) (noACAs) in patients with Ph+ ALL receiving TKI before transplantation. The groups did not differ significantly in age, gender, or interval from diagnosis to transplantation. More patients with ACAs received PB grafts (86.4% vs. 78.1%, p = 0.03), while more patients in the noACAs group received myeloablative conditioning (87% vs. 75.9%, p = 0.003).
Open in Who Shared Issue with article?

Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT

|
By Ryszard Swoboda, Myriam Labopin, Nicolaus Kröger, Matthias Stelljes, Thomas Schroeder, Peter Dreger, Gesine Bug, Andrew McDonald, Montserrat Rovira, Igor Wolfgang Blau, Desiree Kunadt, Regis de Latour, Werner Rabitsch, Matthias Eder, Marie Therèse Rubio, Alexandros Spyridonidis, Zinaida Perić, Sebastian Giebel, Mohamad Mohty Verified, Fabio Ciceri, Tülay Özçelik
| Nature Verified
Abstract There are very limited data on treosulfan (Treo)-based conditioning before allogeneic hematopoietic stem cell transplantation (alloHSCT) in acute lymphoblastic leukemia. We aimed to compare fludarabine with Treo (FluTreo) or total body irradiation (FluTBI) in this setting. The final matched-pair analysis included ALL patients transplanted in complete remission after FluTreo (n = 153) or FluTBI (n = 431). The median patient age was 56.5 and 54.1 years, respectively.
Open in Who Shared Issue with article?
See all 92 licensed articles (99 Total)